Table 1. Demographics of the patient cohort screened for EURTAC trial.
| SLCG LDT MD | SLCG LDT MND | |||
| EGFR PCR tested | EGFR PCRnot tested | EGFR PCR tested | EGFR PCR not tested | |
| Total | 172 | 53 | 303 | 489 |
| Age (years), mean ± SD | 64.1±10.4 | 62.9±10.4 | 61.7±10.6 | 61.7±10.6 |
| Sex, n (%) | ||||
| Male | 41 (23.8) | 14 (26.4) | 179 (59.1) | 281 (57.5) |
| Female | 131 (76.2) | 39 (73.6) | 124 (40.9) | 208 (42.5) |
| Race/ethnicity, n (%) | ||||
| Caucasian | 168 (97.7) | 52 (98.1) | 296 (97.7) | 481 (98.4) |
| Other* | 4 (2.3) | 1 (1.9) | 7 (2.3) | 8 (1.6) |
| Smoking status, n (%) | ||||
| Never smoked | 124 (72.1) | 31 (58.5) | 74 (24.4) | 133 (27.2) |
| Past/currentsmoker | 47 (27.3) | 22 (41.5) | 219 (72.3) | 339 (69.3) |
| Unknown | 1 (0.6) | 0 (0.0) | 10 (3.3) | 17 (3.5) |
| Stage IIIB | 13 (7.6) | 2 (3.8) | 17 (5.6) | 40 (8.2) |
| Stage IV | 157 (91.3) | 50 (94.3) | 277 (91.4) | 432 (88.3) |
| Other* | 2 (1.2) | 1 (1.9) | 9 (3.0) | 17 (3.5) |
| Histology, n (%) | ||||
| Adenocarcinoma | 156 (90.7) | 47 (88.7) | 266 (87.8) | 407 (83.2) |
| BronchioalveolarCarcinoma | 1 (0.6) | 2 (3.8) | 5 (1.7) | 16 (3.3) |
| Other* | 15 (8.7) | 4 (7.5) | 32 (10.6) | 66 (13.5) |
*Other includes subjects with no information available. LDT = laboratory-developed test; MD = mutation detected; MND = mutation not detected.
SLCG inconclusive (n = 27) data not shown.